The case for & against
Bull & Bear analysis
Landos Biopharma (LABP) was a biopharmaceutical company specializing in the development of therapeutics for inflammatory bowel disease (IBD). It had a promising platform focused on novel candidate treatments, including its lead asset, NIM-1324, targeting the LANCL2 immunometabolic mechanism for diseases like ulcerative colitis and Crohn's disease. The company aimed to address unmet medical needs in chronic inflammation and immune-mediated diseases. Following its acquisition by AbbVie in May 2024, Landos Biopharma ceased trading on NASDAQ. The research and development of the former pipeline assets have transitioned to NImmune Biopharma, marking a continuation of the innovative work in this therapeutic area.
Bull says
- ↑AbbVie’s May 24, 2024 acquisition signals strong external pipeline validation
- ↑NIM-1324 met primary and secondary endpoints in Phase 1/preclinical trials
- ↑LANCL2 immunometabolic mechanism offers differentiated efficacy in UC and Crohn’s
- ↑NImmune Biopharma plans Phase 2 trials, targeting Breakthrough Therapy status
- ↑Rising global IBD prevalence boosts market demand for novel treatments
- ↑AbbVie’s resources could accelerate development and commercial launch
Bear says
- ↓Cessation of LABP trading reduces stock liquidity and visibility
- ↓Uncertain financial forecasts post-acquisition heighten long-term value ambiguity
- ↓Phase 2 transition carries regulatory risks without guaranteed approval
- ↓Established therapies (Humira, Stelara) present steep competitive pressure
- ↓Sparse public updates may dampen sentiment until Phase 2 data arrive
- ↓Market may discount pipeline amid transition and competitive landscape